Dr. Balashov is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
725 Albany St
Ste 7BBLDG
Boston, MA 02118Phone+1 617-638-8456Fax+1 617-638-8465
Summary
- Dr. Konstantin E. Balashov is a clinical professor of neurology at Boston University Chobanian & Avedisian School of Medicine and Director of MS Center at Boston Medical Center. He completed neuroimmunology fellowship at Harvard Medical School and has been in clinical practice for 20 years. Dr Balashov has extensive experience in evaluation, diagnosis, and treatment of people with multiple sclerosis and published more than 50 original articles and reviews.
Education & Training
JFK Medical CenterResidency, Neurology, 2001 - 2004
Brooklyn Hospital CenterResidency, Internal Medicine, 1999 - 2000
Harvard Medical SchoolFellowship, 1992 - 1995- Russian Academy of Medical SciencesPhD, 1983 - 1986
- Russian State Medical UniversityMD, Medicine, 1977 - 1983
Russian State Medical UniversityClass of 1983, MD
Certifications & Licensure
MA State Medical License 2004 - 2025
NJ State Medical License 2005 - 2025
NY State Medical License 2009 - 2011- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Clinical Trials
- Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis Start of enrollment: 2007 Apr 01
Publications & Presentations
PubMed
- Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients.Yang Mao-Draayer, Amit Bar-Or, Konstantin Balashov, John Foley, Kyle Smoot
Advances in Therapy. 2024-11-21 - 11 citationsFecal Lcn-2 level is a sensitive biological indicator for gut dysbiosis and intestinal inflammation in multiple sclerosis.Sudhir K Yadav, Naoko Ito, John E Mindur, Hetal Kumar, Mysra Youssef
Frontiers in Immunology. 2022-01-01 - 3 citationsFibrinolysis induced clinical improvement in a patient with multiple sclerosis exacerbation.Konstantin E. Balashov, Suhayl Dhib-Jalbut, Igor Rybinnik
Multiple Sclerosis and Related Disorders. 2020-08-01
Press Mentions
The Multiple Sclerosis Center at Boston Medical Center Recognized as a Center for Comprehensive MS Care by the National MS SocietyJune 14th, 2022
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
